157 related articles for article (PubMed ID: 36202286)
1. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
Ahmed M; Nudy M; Bussa R; Weigel F; Naccarelli G; Maheshwari A
Trends Cardiovasc Med; 2024 Feb; 34(2):101-107. PubMed ID: 36202286
[TBL] [Abstract][Full Text] [Related]
2. Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Bendary A; Bendary M; Salem M
Heart Fail Rev; 2019 Mar; 24(2):245-254. PubMed ID: 30317416
[TBL] [Abstract][Full Text] [Related]
3. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
[TBL] [Abstract][Full Text] [Related]
4. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
[TBL] [Abstract][Full Text] [Related]
5. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
Eur J Heart Fail; 2024 Apr; 26(4):1051-1061. PubMed ID: 38606555
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
7. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial.
Premchand RK; Sharma K; Mittal S; Monteiro R; Dixit S; Libbus I; DiCarlo LA; Ardell JL; Rector TS; Amurthur B; KenKnight BH; Anand IS
J Card Fail; 2014 Nov; 20(11):808-16. PubMed ID: 25187002
[TBL] [Abstract][Full Text] [Related]
8. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
[TBL] [Abstract][Full Text] [Related]
9. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study.
Zipes DP; Neuzil P; Theres H; Caraway D; Mann DL; Mannheimer C; Van Buren P; Linde C; Linderoth B; Kueffer F; Sarazin SA; DeJongste MJL;
JACC Heart Fail; 2016 Feb; 4(2):129-136. PubMed ID: 26682789
[TBL] [Abstract][Full Text] [Related]
10. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Lee VYJ; Houston L; Perkovic A; Barraclough JY; Sweeting A; Yu J; Fletcher RA; Arnott C
Heart Lung Circ; 2024 Feb; 33(2):197-208. PubMed ID: 38320881
[TBL] [Abstract][Full Text] [Related]
12. Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.
Sant'Anna LB; Couceiro SLM; Ferreira EA; Sant'Anna MB; Cardoso PR; Mesquita ET; Sant'Anna GM; Sant'Anna FM
Front Cardiovasc Med; 2021; 8():766676. PubMed ID: 34901227
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
14. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
[TBL] [Abstract][Full Text] [Related]
15. Renal denervation in management of heart failure with reduced ejection fraction: A systematic review and meta-analysis.
Li M; Ma W; Fan F; Yi T; Qiu L; Wang Z; Weng H; Zhang Y; Li J; Huo Y
J Cardiol; 2023 Jun; 81(6):513-521. PubMed ID: 36758670
[TBL] [Abstract][Full Text] [Related]
16. Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fraction.
Anand I; Ardell JL; Gregory D; Libbus I; DiCarlo L; Premchand RK; Sharma K; Mittal S; Monteiro R
Int J Cardiol Heart Vasc; 2020 Aug; 29():100520. PubMed ID: 32509959
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
18. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
[TBL] [Abstract][Full Text] [Related]
19. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]